NCT00003895View on ClinicalTrials.gov

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 1999

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Recurrent MelanomaStage IA MelanomaStage IB MelanomaStage IIA MelanomaStage IIB MelanomaStage IIC MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC Melanoma
Interventions
BIOLOGICAL

HPV 16 E7:12-20

Given SC

BIOLOGICAL

gp100:209-217(210M)

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

97213

Providence Portland Medical Center, Portland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00003895 - Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma | Biotech Hunter | Biotech Hunter